WebJun 15, 2024 · Despite a 26% rise over the last month or so, CRSP stock is still down 20% year-t0-date. A few months back we discussed that investors may get better levels to enter CRSP stock after it surged 3x ... WebFeb 1, 2024 · CRISPR Therapeutics stock (NASDAQ: CRSP), a biotechnology gene editing company focused on developing gene-based medicines for human diseases, has plunged by 14% over the last 10 trading days, and ...
Better Buy: Vertex vs. CRISPR The Motley Fool
WebMar 10, 2024 · Bank of America has a "buy" rating and $116 price target for CRSP stock. Beam Therapeutics Inc. ( BEAM) Beam Therapeutics uses CRISPR technology to … WebJun 15, 2024 · The company’s competitors include Intellia Therapeutics (NTLA) and Editas Medicine (EDIT). These competitors and others are utilizing gene therapy solutions in their business models.... chino short dames
Crispr Therapeutics AG (CRSP) Stock Competitors
WebJun 3, 2024 · Both CRISPR Therapeutics ( CRSP 3.35%) and Intellia Therapeutics ( NTLA -1.36%) offer promising gene editing tools that could alter some medical treatments. … WebCRSP - Crispr Therapeutics Ag Stock Competitors - Barchart.com Get all the relevant market information you need — get it fast, on time, and accurately. FREE 30 Day Trial or Stocks Options ETFs Futures Currencies Investing News Tools Learn Crispr Therapeutics Ag (CRSP) Alerts Watch Help Go To: Other Sectors containing Crispr Therapeutics Ag … WebCRISPR's revenue is the ranked 7th among it's top 10 competitors. The top 10 competitors average 25.6M. Over the last four quarters, CRISPR's revenue has grown by 15566.7%. Specifically, in Q1 2024's revenue was $ < 1M; in Q2 2024, it was $ < 1M; in Q3 2024, it was $ < 1M; in Q4 2024, CRISPR's revenue was $ < 1M. CRISPR News See all … granny game play store